Cure8 trial brief
The study will prospectively evaluate how often dysplasia occurs, how lesions look and behave after endoscopic resection, and what factors predict local or distant recurrence—information that could change surveillance and treatment choices for people with long-standing IBD.
Adults with long-standing ulcerative colitis or colonic Crohn's disease, gastroenterologists/endoscopists, and researchers focused on IBD-associated colorectal neoplasia.
This is a clinicaltrials.gov trial record for a planned (not yet recruiting) observational study enrolling about 800 adults with Crohn's disease or ulcerative colitis at increased colorectal dysplasia risk.
Participants will undergo high-definition colonoscopic surveillance with characterization (endoscopy and histology) of dysplastic lesions and follow-up for up to 7 years to measure prevalence, incidence, resection outcomes (including completeness of resection), and local or distant recurrence.
The study is focused on real-world endoscopic practice in the era of high-definition scopes and advanced resection techniques (including endoscopic submucosal dissection) and seeks to inform which lesions are suitable for endoscopic treatment versus colectomy.
This is a registered, not-yet-recruiting observational study (planned enrollment ~800) on ClinicalTrials.gov. It describes planned surveillance and long-term follow-up for dysplasia in IBD but does not provide study results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD face an elevated lifetime risk of colitis-associated cancer; improved detection and risk prediction could lead to earlier treatment and better outcomes. AI could make surveillance more accurate and...
Tertiary lymphoid organs form in IBD and may influence disease course; understanding how lymphatic S1PR1 controls TLOs could reveal new targets to modify intestinal inflammation without broad immunosuppression.
This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...
